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The burden of latent multidrug-resistant tuberculosis
In the past 10 years, there has been renewed interest in 
the early phases of the natural history of tuberculosis.1 
Estimates suggest that around 25% of the world’s 
population could have latent tuberculosis infection,2 
5–10% of whom will develop active disease during their 
lifetime3 (10% annually among people with HIV).4 Failure 
to implement effective tuberculosis control measures to 
manage latent infection threatens elimination goals.
Groups at high risk of active tuberculosis are the focus 
of programmatic management of latent tuberculosis 
infection.5 Once active disease is ruled out, tuberculosis 
preventive therapy can be offered. However, such therapy 
is thought to be ineffective against multidrug-resistant 
(MDR) strains (ie, those resistant to isoniazid or rifampicin, 
or both), and is thus rarely used to treat contacts of people 
with MDR tuberculosis.
In The Lancet Infectious Diseases, Gwenan Knight 
and colleagues6 investigated the global burden of 
latent tuberculosis to provide the first estimates of the 
prevalence of latent MDR disease. They used surveillance 
and survey data, estimated annual risks of infection, and 
informative priors for patterns of increase to develop 
and validate a novel cohort method to calculate this 
burden. Knight and colleagues estimated that around 
19 million people could be latently infected with MDR 
tuberculosis (10% of whom were infected in 2013 
and 2014—ie, the most recent 2 years included in the 
model), representing around 1·2% of the total burden 
of latent infection. Children younger than 15 years, who 
progress to active disease more quickly than adults and 
therefore are a sentinel event suggesting recent local 
transmission, had more than double the risk of latent 
MDR tuberculosis infection that adults had. These data 
show that transmission of MDR strains of tuberculosis 
is worryingly high and probably increasing, and should 
be urgently addressed. Knight and colleagues also 
estimated that, even if all tuberculosis transmission 
was halted, reactivation of latent disease would mean 
that the future burden of MDR disease would still be 
substantial.6 Their work thus clearly emphasises the need 
for interventions to limit both transmission of MDR 
tuberculosis and reactivation of latent MDR disease.
Knight and colleagues’ findings have important 
implications at the individual and population level 
and for policy. Given that the prevalence of latent MDR 
tuberculosis infection will continue to rise if MDR 
transmission rates persist, an increasing proportion 
of people—and children especially—with latent 
infections7 might not benefit from recommended 
tuberculosis preventive therapy regimens, and thus 
will be at increased risk of developing active MDR 
tuberculosis.8 At the population level, as the prevalence 
of latent tuberculosis infection decreases, the partial 
protective effect against reinfection or reactivation 
that latent infection with drug-susceptible tuberculosis 
provides9 against MDR strains will also diminish, 
thus increasing the risk of latent infection with MDR 
strains. In the meantime, Knight and colleagues’ study 
emphasises the need to strengthen epidemiological 
surveillance of MDR tuberculosis and programmatic 
management of active and latent infections to 
reduce transmission of MDR disease (and thus 
the number of people with latent MDR tuberculosis). 
Only 25% of people with active MDR tuberculosis are 
detected (compared with 64% of people with all types 
of tuberculosis in 2017).10 Early identification of cases, 
prompt initation of highly effective treatment, and close 
treatment follow-up will help to shorten the infectious 
period, and MDR tuberculosis preventive therapies will 
clear infections or prevent disease progression.
Further research priorities for diagnosis and treatment 
of latent MDR tuberculosis have been identified by 
Knight and colleagues. First, there is an urgent need to 
accelerate research into preventive therapy regimens 
for household contacts of people with confirmed MDR 
tuberculosis. Observational studies suggest that the 
contacts of people with MDR tuberculosis might benefit 
from tuberculosis preventive therapy, but no results 
from clinical trials have been published yet.11 Second, 
novel diagnostics or biosignatures that can identify the 
people in whom latent infection will progress to active 
tuberculosis—and thus who are likely to benefit from 
tuberculosis preventive therapy—are needed.12 Tools 
that can identify the resistance pattern of the infecting 
Mycobacterium tuberculosis strain are unlikely to be 
developed soon. However, given that contacts of cases 
with MDR tuberculosis might develop drug-susceptible 
or MDR tuberculosis,13 there is a clear need for universal 
tuberculosis preventive therapy (ie, treatment that is 
effective irrespective of the drug resistance pattern). 
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Universal tuberculosis preventive therapy would be 
of great relevance in settings with a high prevalence 
of MDR tuberculosis, such as eastern Europe, where 
MDR strains account for more than 25% of tuberculosis 
transmission in several countries.
Although Knight and colleagues’ study advances 
approaches to and assumptions in modelling of latent 
tuberculosis infection, gaps remain. Most models 
of the latent tuberculosis burden assume lifelong 
infections2,6—a contentious assumption given that 
some infections clear naturally or after treatment 
with sterilising tuberculosis preventive therapy. The 
definition of latent tuberculosis infection used did 
not account for mixed infections, and future models 
could examine the effect of mixed infections on 
susceptibility to reinfection or reactivation.9 Similarly, 
the reactivation rate could differ between recently 
infected and remotely infected individuals,14 and thus 
could affect the estimated burden of latent infection. 
It would be valuable to forecast the burden of latent 
MDR tuberculosis depending on different scenarios 
of progression and interventions towards the End TB 
targets at different timepoints, especially in children 
and young people. Additionally, sensitivity analysis 
with different MDR tuberculosis fitness cost rates 
and progression to active MDR disease would help to 
further clarify the magnitude and threat of the MDR 
tuberculosis epidemic.
There is a need to strengthen surveillance systems 
for detection of MDR tuberculosis and adequate 
patient management for early initiation of second-line 
treatment and treatment follow-up. The tuberculosis 
epidemic will not be ended without tackling people 
who are latently infected, and thus an increasing focus 
on the left side of the curve of the natural history 
of tuberculosis should be considered in countries 
with the highest burden of infection, so that the 
criteria for recommending preventive therapies can be 
progressively expanded.
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